These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25578890)

  • 1. Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.
    Harsing LG; Timar J; Szabo G; Udvari S; Nagy KM; Marko B; Zsilla G; Czompa A; Tapolcsanyi P; Kocsis A; Matyus P
    Curr Pharm Des; 2015; 21(17):2291-303. PubMed ID: 25578890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review).
    Harsing LG; Zsilla G; Matyus P; Nagy KM; Marko B; Gyarmati Z; Timar J
    Acta Physiol Hung; 2012 Mar; 99(1):1-17. PubMed ID: 22425803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycine transporter-1: a new potential therapeutic target for schizophrenia.
    Hashimoto K
    Curr Pharm Des; 2011; 17(2):112-20. PubMed ID: 21355838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
    Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
    Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study.
    Harsing LG; Gacsalyi I; Szabo G; Schmidt E; Sziray N; Sebban C; Tesolin-Decros B; Matyus P; Egyed A; Spedding M; Levay G
    Pharmacol Biochem Behav; 2003 Mar; 74(4):811-25. PubMed ID: 12667895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes.
    Herdon HJ; Godfrey FM; Brown AM; Coulton S; Evans JR; Cairns WJ
    Neuropharmacology; 2001 Jul; 41(1):88-96. PubMed ID: 11445189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.
    Nagy K; Marko B; Zsilla G; Matyus P; Pallagi K; Szabo G; Juranyi Z; Barkoczy J; Levay G; Harsing LG
    Neurochem Res; 2010 Dec; 35(12):2096-106. PubMed ID: 20725779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.
    Hashimoto K; Fujita Y; Ishima T; Chaki S; Iyo M
    Eur Neuropsychopharmacol; 2008 Jun; 18(6):414-21. PubMed ID: 17804206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
    Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
    Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity.
    Núñez E; Martínez-Maza R; Geerlings A; Aragón C; López-Corcuera B
    Neuropharmacology; 2005 Nov; 49(6):922-34. PubMed ID: 16143353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model.
    Mohammadzadeh A; Lakatos PP; Balogh M; Zádor F; Karádi DÁ; Zádori ZS; Király K; Galambos AR; Barsi S; Riba P; Benyhe S; Köles L; Tábi T; Szökő É; Harsing LG; Al-Khrasani M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33804568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
    Kinney GG; Sur C; Burno M; Mallorga PJ; Williams JB; Figueroa DJ; Wittmann M; Lemaire W; Conn PJ
    J Neurosci; 2003 Aug; 23(20):7586-91. PubMed ID: 12930797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine.
    Mallorga PJ; Williams JB; Jacobson M; Marques R; Chaudhary A; Conn PJ; Pettibone DJ; Sur C
    Neuropharmacology; 2003 Oct; 45(5):585-93. PubMed ID: 12941372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine transporter inhibitors: A new avenue for managing neuropathic pain.
    Al-Khrasani M; Mohammadzadeh A; Balogh M; Király K; Barsi S; Hajnal B; Köles L; Zádori ZS; Harsing LG
    Brain Res Bull; 2019 Oct; 152():143-158. PubMed ID: 31302238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia.
    Kumar A; Akhtar A; Kuhad A; Sah SP
    Exp Brain Res; 2023 Feb; 241(2):451-467. PubMed ID: 36577922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal alteration of spreading depression by the glycine transporter type-1 inhibitors NFPS and Org-24461 in chicken retina.
    Kertesz S; Szabo G; Udvari S; Levay G; Matyus P; Harsing LG
    Brain Res; 2013 Jan; 1492():1-6. PubMed ID: 23178696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.